New Section 232 tariffs of up to 100% on patented pharmaceuticals and ingredients will apply to many U.S. imports, with country- and agreement-based reductions.

REGULATORY BRIEFING – SECTION 232 TARIFFS ON PATENTED PHARMACEUTICAL PRODUCTS

1. What changed

• The President has imposed new Section 232 tariffs on imports of patented pharmaceutical products and their ingredients.
• Legal basis: Section 232 of the Trade Expansion Act of 1962, as amended (national security measure).
• Default tariff rate: 100% ad valorem on covered patented pharmaceuticals and associated ingredients.
• Differentiated rates apply based on:
• Country of origin (trade-deal partners vs others)
• Whether the importer/producer has onshoring and/or MFN pricing agreements with U.S. agencies
• Product type (patented vs generic/biosimilar; specialty categories)
• The measure follows a Section 232 investigation concluding that imports of patented pharmaceuticals and related ingredients threaten to impair U.S. national security.

2. Affected products

2.1 Scope of coverage

• Covered:
• Patented pharmaceutical products imported into the United States.
• Pharmaceutical ingredients associated with patented products (likely including active pharmaceutical ingredients (APIs) and possibly key intermediates used in patented drugs).
• Not covered at this time:
• Generic pharmaceutical products.
• Biosimilars.
• Associated ingredients for generics and biosimilars.
• Exempt specialty products (subject to conditions):
• Orphan drugs.
• Drugs for animal health.
• Certain other specialty pharmaceutical products that either:

– Originate in specified trade-deal countries, or

– Meet an urgent public health need.

2.2 HTS classification

• The fact sheet does not specify HTS subheadings or Chapter 99 numbers, but in practice, coverage will likely involve:
• HTS Chapter 29 (e.g., 2933–2936, 2937, 2939, 2941) for APIs and intermediates.
• HTS Chapter 30 (e.g., 3002–3004, 3006) for finished pharmaceutical products.
• A separate Presidential Proclamation and/or implementing instructions from USTR/CBP are expected to:
• Identify specific HTS subheadings.
• Establish any new Chapter 99 numbers for Section 232 duties on these products.

Compliance teams must:

• Map all imported patented pharmaceuticals and related ingredients to their HTS codes.
• Monitor for the forthcoming official list of covered HTS codes and any Chapter 99 provisions.

3. Tariff rate structure

3.1 Default rate

• Standard Section 232 rate on covered patented pharmaceuticals and ingredients:
• 100% ad valorem tariff on the customs value of the imported goods.

3.2 Country-based reduced rates (trade-deal countries)

• European Union, Japan, Korea, Switzerland, Liechtenstein:
• If the pharmaceutical product is from these jurisdictions, a 15% tariff will apply (instead of 100%), assuming no other special agreement is in place.
• United Kingdom:
• A lower tariff will apply, subject to the recently concluded UK pharmaceutical agreement.
• The exact rate is not specified in the fact sheet and will need to be confirmed in the implementing documents.

3.3 Agreement-based preferential rates

• MFN pricing + onshoring agreements (with HHS and Commerce):
• Tariff rate: 0% (full exemption from the Section 232 tariff).
• Duration: Through January 20, 2029.
• Conditions: Company must enter into both:

– A Most Favored Nation (MFN) pricing agreement with the Department of Health and Human Services (HHS), and

– An onshoring agreement with the Department of Commerce.

• Onshoring agreement only (no MFN pricing agreement):
• Tariff rate: 20%.
• Applies to companies that enter into onshoring agreements with Commerce but do not have MFN pricing agreements with HHS.

3.4 Exemptions and exclusions

• Generic pharmaceuticals, biosimilars, and associated ingredients:
• Tariff rate: 0% (not subject to these Section 232 tariffs at this time).
• Reassessment: Policy will be reassessed in one year; future inclusion is possible.
• Specialty pharmaceutical products:
• Orphan drugs, animal health drugs, and certain other specialty products will be exempt if:

– They are from trade-deal countries (EU, Japan, Korea, Switzerland, Liechtenstein, UK under its agreement), or

– They meet an urgent public health need.

• Details on how “urgent public health need” will be determined are not provided and will likely be clarified in subsequent guidance.

3.5 Monitoring and enforcement

• The Proclamation will establish:
• Strong monitoring and enforcement mechanisms.
• External audits.
• Potential tariff increases on future and past imports for non-compliance or misrepresentation.

4. Effective dates and timelines

• Tariff implementation timing:
• Large companies: Tariffs take effect in 120 days from the date of the announcement (April 2, 2026).
• Smaller companies: Tariffs take effect in 180 days from the date of the announcement.
• Key date:
• Announcement date: April 2, 2026.
• Effective date for large companies: Approximately July 31, 2026 (120 days from April 2, 2026; confirm exact date in the Proclamation).
• Effective date for smaller companies: Approximately September 29, 2026 (180 days from April 2, 2026; confirm exact date in the Proclamation).
• Duration of 0% rate for MFN + onshoring agreements:
• Through January 20, 2029.
• Reassessment of generics/biosimilars:
• Policy on generic pharmaceuticals, biosimilars, and associated ingredients will be reassessed one year after implementation; importers should anticipate potential future changes.

5. Required actions for importers, brokers, and compliance teams

5.1 Product and HTS mapping

• Identify all imported products that may be covered:
• Determine which imported pharmaceuticals are patented vs generic/biosimilar.
• Identify associated ingredients (APIs, intermediates) linked to patented products.
• Map these products to HTS codes:
• Confirm current HTS classifications for all potentially affected products.
• Prepare to apply any new Chapter 99 numbers once published.

5.2 Country-of-origin and supply chain review

• Determine country of origin for each covered product:
• Distinguish products originating in:

– EU, Japan, Korea, Switzerland, Liechtenstein (15% rate baseline).

– United Kingdom (special lower rate under UK pharmaceutical agreement).

– All other countries (default 100% rate unless agreements apply).

• Review and document origin determination methodologies (substantial transformation, etc.) to withstand audits.

5.3 Evaluate eligibility for reduced or zero tariffs

• Assess feasibility of entering into agreements:
• MFN pricing agreement with HHS.
• Onshoring agreement with the Department of Commerce.
• For companies considering these agreements:
• Engage internal stakeholders (legal, regulatory, pricing, manufacturing, supply chain) to evaluate:

– Commercial implications of MFN pricing.

– Capital and operational commitments required for onshoring.

• Initiate contact with HHS and Commerce once pathways are published to understand application processes and timelines.
• For companies not entering agreements:
• Model financial impact of 100% tariffs (or 15%/UK rate where applicable) on landed cost and pricing.
• Consider supply chain restructuring (e.g., shifting production to trade-deal countries or U.S. onshoring) to mitigate tariff exposure.

5.4 Customs entry and broker instructions

• Update broker instructions:
• Communicate which SKUs/HTS lines are subject to Section 232 tariffs and applicable rates by country and by agreement status.
• Once Chapter 99 numbers are published, ensure brokers apply them correctly on CBP entries.
• Internal controls:
• Implement controls to distinguish patented vs generic/biosimilar products in customs data.
• Ensure that any claimed exemptions (e.g., orphan drugs, urgent public health need) are supported by robust documentation.

5.5 Financial planning and contracts

• Pricing and contracts:
• Review existing supply and distribution contracts for tariff pass-through clauses.
• Renegotiate where necessary to address the new Section 232 costs.
• Budgeting and forecasting:
• Incorporate new tariff rates into cost models and budgets starting from the relevant effective dates (120/180 days).

5.6 Compliance and audit readiness

• Documentation:
• Maintain evidence of patent status, product type (patented vs generic/biosimilar), and any specialty status (orphan, animal health, urgent public health need).
• Retain all documentation related to MFN pricing and onshoring agreements, including formal agreements and correspondence with HHS and Commerce.
• Audit preparedness:
• Prepare for external audits and potential retroactive tariff adjustments.
• Conduct internal reviews of classification, origin, and valuation practices for covered products.

5.7 Monitoring future developments

• Monitor for:
• The official Presidential Proclamation text and any annexes listing HTS codes.
• Implementing guidance from:

– U.S. Customs and Border Protection (CBP).

– U.S. Department of Commerce.

– U.S. Department of Health and Human Services (HHS).

– Office of the U.S. Trade Representative (USTR).

• Any subsequent Federal Register notices establishing procedures for exclusions, public health exemptions, or agreement enrollment.
• The one-year reassessment outcome for generics and biosimilars.

6. Industries and stakeholders most impacted

• Brand-name pharmaceutical manufacturers and importers of patented drugs.
• Importers of patented-drug APIs and key intermediates, especially those sourcing from non-trade-deal countries.
• Distributors and wholesalers handling imported patented pharmaceuticals.
• Healthcare providers and payers indirectly affected by cost changes.
• Contract manufacturing organizations (CMOs) producing patented drugs or ingredients for U.S. import.

7. Key risk areas

• Misclassification of products as generic/biosimilar when they are covered patented products.
• Incorrect origin determinations leading to underpayment of tariffs (e.g., claiming EU origin when substantial transformation occurred elsewhere).
• Improper use of exemptions (orphan, animal health, urgent public health need) without adequate substantiation.
• Failure to timely adjust systems and broker instructions by the 120/180-day effective dates.
• Non-compliance with MFN or onshoring agreement terms, potentially triggering loss of preferential rates and retroactive tariff assessments.

8. References and further information

Note: The fact sheet references a Presidential Proclamation and agency actions but does not provide direct URLs. Compliance teams should monitor the following sources:

• White House Fact Sheet (April 2, 2026):
• Main White House site: https://www.whitehouse.gov
• Search for: “Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products”

• Presidential Proclamation and implementing details:
• Federal Register: https://www.federalregister.gov
• Search terms: “Section 232 pharmaceuticals”, “patented pharmaceutical products tariffs”, “pharmaceutical ingredients Section 232”.

• U.S. Customs and Border Protection (CBP):
• CBP Trade page: https://www.cbp.gov/trade
• Look for cargo systems messaging service (CSMS) notices and guidance on new Section 232 pharmaceutical tariffs and any Chapter 99 codes.

• U.S. Department of Commerce:
• https://www.commerce.gov
• For onshoring agreement frameworks and application procedures.

• U.S. Department of Health and Human Services (HHS):
• https://www.hhs.gov
• For MFN pricing agreement details and enrollment pathways.

Action summary:

• Immediately inventory all imported patented pharmaceuticals and related ingredients and map to HTS and origin.
• Model financial impact under 100%, 20%, 15%, and UK-specific rates.
• Decide whether to pursue MFN pricing and/or onshoring agreements and prepare to engage with HHS and Commerce.
• Prepare systems, broker instructions, and documentation to comply by the 120/180-day implementation deadlines and to withstand audits and enforcement under the new Section 232 regime.